BR100 Decreased By (-0.4%)
BR30 Decreased By (-0.64%)
KSE100 Decreased By (-0.29%)
KSE30 Decreased By (-0.21%)
AGHA 6.60 Decreased By ▼ -0.07 (-1.05%)
BECO 4.39 Increased By ▲ 0.04 (0.92%)
BML 55.31 Decreased By ▼ -0.86 (-1.53%)
BOP 29.98 Decreased By ▼ -0.14 (-0.46%)
CNERGY 12.70 Decreased By ▼ -0.28 (-2.16%)
CSIL 5.18 Decreased By ▼ -0.13 (-2.45%)
FCCL 50.99 Decreased By ▼ -0.66 (-1.28%)
FFL 14.42 Decreased By ▼ -0.07 (-0.48%)
FNEL 1.22 Increased By ▲ 0.01 (0.83%)
KEL 5.96 Decreased By ▼ -0.10 (-1.65%)
KOSM 5.55 Decreased By ▼ -0.29 (-4.97%)
LOTCHEM 26.20 Increased By ▲ 0.03 (0.11%)
MLCF 90.00 Decreased By ▼ -1.23 (-1.35%)
NBP 161.50 Decreased By ▼ -2.69 (-1.64%)
NCPL 52.65 Decreased By ▼ -0.53 (-1%)
NPL 57.71 Decreased By ▼ -1.41 (-2.38%)
OGDC 315.31 Increased By ▲ 1.92 (0.61%)
PACE 9.75 Decreased By ▼ -0.02 (-0.2%)
PAEL 34.75 Decreased By ▼ -0.49 (-1.39%)
PIBTL 14.19 Decreased By ▼ -0.52 (-3.54%)
PPL 220.50 Decreased By ▼ -0.86 (-0.39%)
PRL 90.25 Decreased By ▼ -0.97 (-1.06%)
PTC 58.90 Decreased By ▼ -0.29 (-0.49%)
SSGC 23.32 Increased By ▲ 0.02 (0.09%)
TBL 8.68 Decreased By ▼ -0.07 (-0.8%)
TELE 7.39 Decreased By ▼ -0.22 (-2.89%)
TPL 21.10 Decreased By ▼ -0.93 (-4.22%)
TPLP 12.07 Decreased By ▼ -0.49 (-3.9%)
TREET 21.40 Decreased By ▼ -0.33 (-1.52%)
TRG 54.40 Decreased By ▼ -1.39 (-2.49%)
World

Australia to buy 10mn additional doses of Pfizer COVID-19 vaccine

  • "These additional vaccines have been secured consistent with our requirements," Morrison told reporters in Canberra.
Published Updated
By

SYDNEY: Australia will buy 10 million additional doses of the COVID-19 vaccine jointly developed by US drugmaker Pfizer Inc and Germany's BioNTech , Prime Minister Scott Morrison said on Thursday.

"These additional vaccines have been secured consistent with our requirements," Morrison told reporters in Canberra.

Australia last week approved the Pfizer-BioNTech COVID-19 vaccine for use for people aged 16 years and older, and expects to begin inoculation at 80,000 doses per week by the end of February.

Comments

Comments are closed for this article.